2[1]Honerjager P. Pharmacology of bipyridine phosphodiesterase Ⅱ inhibitors. Am Heart J, 1991,121:1939
3[2]Shipley JB, Tolman D, Haotills A, et al. Ailribobe:basic and clinical pharmacology and acute and chronic mamagement. Am J Med Sci, 1996,311(6):286
4[3]John F, Butterworth IV, Robert L. ct al. A new pharma cokinetic and pharmacodynamic evaluation of milrinone in adult undergoing cardiac surgery. Anesth Aolg, 1995,81: 783
5[4]Biddle TL, Benotti JR, Creager MA, ct al. Comparison of intravenous milrinone and doutamin for congestive heart failure secondary to either ischemic or dilated cardiomyopathy. Am J Cardiol, 1987,59:1345
6Bhat G.Predictors of clinical outcome in advnced heart fail-ure patients on conllnuous intravenous milfinone therapy[J].ASAIO,2006,52(6):677-681.
7Volkova Siu.Prognostic value of changes in concentration ofbrain natriuretic peptide,TNF-alpha factor and interleukin-6 in chronic cardiac failure[J].Klin Med(Mosk),2008,86(7):18-22.
10Anderson JL. Hemodynamic and clinical benefits with intravenous milrinone in severe heart failure: Results of multicenter study in the United States [J]. Am Heart J,1991,121(6 Pt 2):1956.
